Synagis' Special Status Under Health Care Reform
This article was originally published in The Pink Sheet Daily
The new Medicaid rebate rules don't bite as deeply for drugs approved exclusively for pediatric use. It turns out that AstraZeneca/MedImmune's Synagis is the only therapy to qualify.
You may also be interested in...
Big Pharma's first quarter earnings reports offered the first estimates of the impact from health care reform on the industry. Wall Street was taken aback at the size of some of the hits. But not everyone is equally affected-nor will everyone be feeling the same burden when new impacts begin in 2011.
Biden’s incoming Secretary of Health is a fan of ‘march in’ rights as a cost-containment tool for medicines. Two hold-overs from Trump Presidency may slow him down.
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.